Assignee
ORYZON GENOMICS SA
ES·22 granted patents·28 pending applications·93 citations·filing 2005–2023
Top patents by PatentIndex Score
50 records- 0196US9149447B2Lysine specific demethylase-1 inhibitors and their useORYZON GENOMICS SA·Filed 2014·Granted Oct 6, 2015·20 cites·5 claims
- 0289US9670136B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2016·Granted Jun 6, 2017·8 cites·26 claims
- 0387US9708309B2Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical useORYZON GENOMICS SA·Filed 2015·Granted Jul 18, 2017·7 cites·12 claims
- 0486US9676701B2Cyclopropylamine derivatives useful as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2015·Granted Jun 13, 2017·7 cites·20 claims
- 0586US9487512B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2012·Granted Nov 8, 2016·8 cites·60 claims
- 0686US9469597B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2012·Granted Oct 18, 2016·8 cites·14 claims
- 0784US9944601B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2016·Granted Apr 17, 2018·4 cites·19 claims
- 0880US9790196B2Lysine demethylase inhibitors for diseases and disorders associated with FlaviviridaeORYZON GENOMICS SA·Filed 2013·Granted Oct 17, 2017·8 cites·15 claims
- 0979US11013698B2Combinations of LSD1 inhibitors for the treatment of hematological malignanciesORYZON GENOMICS SA·Filed 2017·Granted May 25, 2021·2 cites·18 claims
- 1078US11034991B2Methods to determine KDM1A target engagement and chemoprobes useful thereforORYZON GENOMICS SA·Filed 2017·Granted Jun 15, 2021·2 cites·12 claims
- 1178US9908859B2Lysine demethylase inhibitors for myeloproliferative disordersORYZON GENOMICS SA·Filed 2014·Granted Mar 6, 2018·6 cites·16 claims
- 1277US10221125B2Solid formsORYZON GENOMICS SA·Filed 2016·Granted Mar 5, 2019·2 cites·34 claims
- 1376US10329256B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2018·Granted Jun 25, 2019·1 cites·19 claims
- 1475US10265279B2Combinations of LSD1 inhibitors for use in the treatment of solid tumorsORYZON GENOMICS SA·Filed 2017·Granted Apr 23, 2019·4 cites·14 claims
- 1575US10214477B2(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitorsORYZON GENOMICS SA·Filed 2017·Granted Feb 26, 2019·1 cites·8 claims
- 1674US10233178B2Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical useORYZON GENOMICS SA·Filed 2017·Granted Mar 19, 2019·1 cites·5 claims
- 1771US10780081B2Method of treating multiple sclerosis employing a LSD1-inhibitorORYZON GENOMICS SA·Filed 2017·Granted Sep 22, 2020·1 cites·19 claims
- 1871US2024226069A1Vafidemstat for use in treating autism spectrum disordersORYZON GENOMICS SA·Filed 2023·Application pending·0 cites
- 1970US12195783B2Methods to determine KDM1A target engagement and chemoprobes useful thereforORYZON GENOMICS SA·Filed 2021·Granted Jan 14, 2025·0 cites·13 claims
- 2070US10202330B2Lysine specific demethylase-1 inhibitors and their useORYZON GENOMICS SA·Filed 2015·Granted Feb 12, 2019·1 cites·2 claims
- 2163US12564559B2Combinations of LSD1 inhibitors for use in the treatment of solid tumorsORYZON GENOMICS SA·Filed 2022·Granted Mar 3, 2026·0 cites·20 claims
- 2263US7745127B2Molecular diagnostic method for dementia with lewy bodiesORYZON GENOMICS SA·Filed 2005·Granted Jun 29, 2010·2 cites·1 claims
- 2363US2022331265A1Combinations of lsd1 inhibitors for the treatment of hematological malignanciesORYZON GENOMICS SA·Filed 2021·Application pending·0 cites
- 2462US2022288039A1Vafidemstat for use in treating autism spectrum disordersORYZON GENOMICS SA·Filed 2020·Application pending·0 cites
- 2560US2024277673A1Methods of treating behavior alterationsORYZON GENOMICS SA·Filed 2023·Application pending·0 cites
- 2659US2023026909A11,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitorsORYZON GENOMICS SA·Filed 2022·Application pending·0 cites
- 2758US2010087331A1Method of nucleic acid analysisORYZON GENOMICS SA·Filed 2009·Application pending·0 cites
- 2858US2010022409A1Method of nucleic acid analysis to analyze the methylation patternORYZON GENOMICS SA·Filed 2009·Application pending·0 cites
- 2956US2025073232A1Combinations of lsd1 inhibitors for treating myeloid cancersORYZON GENOMICS SA·Filed 2022·Application pending·0 cites
- 3053US2017209432A1Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disordersORYZON GENOMICS SA·Filed 2016·Application pending·0 cites
- 3152US2025275969A1Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitorsORYZON GENOMICS SA·Filed 2023·Application pending·0 cites
- 3252US2025295660A1Methods of treating nf1-mutant tumors using lsd1 inhibitorsORYZON GENOMICS SA·Filed 2023·Application pending·0 cites
- 3350US2022151998A1Methods of treating borderline personality disorderORYZON GENOMICS SA·Filed 2020·Application pending·0 cites
- 3450US2022151999A1Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstatORYZON GENOMICS SA·Filed 2020·Application pending·0 cites
- 3548US2016081947A1Selective lsd1 and dual lsd1/mao-b inhibitors for modulating diseases associated with alterations in protein conformationORYZON GENOMICS SA·Filed 2015·Application pending·0 cites
- 3646US12522598B23-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as HDAC6 inhibitorsORYZON GENOMICS SA·Filed 2020·Granted Jan 13, 2026·0 cites·36 claims
- 3744US2020339569A11,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitorsORYZON GENOMICS SA·Filed 2018·Application pending·0 cites
- 3841US2021228490A1Stable pharmaceutical formulationORYZON GENOMICS SA·Filed 2019·Application pending·0 cites
- 3941US2016000768A1Cyclopropylamine inhibitors of oxidasesORYZON GENOMICS SA·Filed 2015·Application pending·0 cites
- 4038US2020323828A1Methods of treating behavior alterationsORYZON GENOMICS SA·Filed 2018·Application pending·0 cites
- 4138US2016045456A1Phenylcyclopropylamine derivatives and their medical useORYZON GENOMICS SA·Filed 2015·Application pending·0 cites
- 4236US2022175698A1Combinations of iadademstat for cancer therapyORYZON GENOMICS SA·Filed 2020·Application pending·0 cites
- 4335US2019256930A1Biomarkers for determining responsiveness to lsd1 inhibitorsORYZON GENOMICS SA·Filed 2017·Application pending·0 cites
- 4434US2018284095A1Biomarkers associated with lsd1 inhibitors and uses thereofORYZON GENOMICS SA·Filed 2016·Application pending·0 cites
- 4534US2010240656A1Compounds as hsp90 inhibitorsORYZON GENOMICS SA·Filed 2008·Application pending·0 cites
- 4632US2019153538A1Gene expression biomarkers for personalized cancer care to epigenetic modifying agentsORYZON GENOMICS SA·Filed 2016·Application pending·0 cites
- 4732US2019256929A1Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agentsORYZON GENOMICS SA·Filed 2017·Application pending·0 cites
- 4831US2010035762A1Prognostic Methods in Colorectal CancerORYZON GENOMICS SA·Filed 2007·Application pending·0 cites
- 4930US2010285483A1Molecular diagnostic method and treatment in dementia with Lewy bodiesORYZON GENOMICS SA·Filed 2010·Application pending·0 cites
- 5023US2010247543A1Treatment and prevention of neurodegenerative diseasesORYZON GENOMICS SA·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ORYZON GENOMICS SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →